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IntroductIon
In Italy, lung carcinoma represents the third most frequently diagnosed tumors (11% of 
the total of tumors), excluding skin cancers, and the first leading cause of death from cancer 
for males (27%) and the third for females (11%) [1]. In 2017, approximately 41,800 new 
cases were estimated, of which 28,000 related to males and 13,600 to females [1]. Since the 
early stages of lung cancer do not show any symptoms – or they show non-specific symp-
toms – at the time of diagnosis, the majority of patients show a locally advanced or metastatic 
disease [2].
Clinically, lung carcinoma can be distinguished into two types, which together describe 
over 95% of cancers affecting this organ: microcytoma – or Small-Cell Lung Cancer (SCLC) 
– which accounts for approximately 15% of lung carcinomas, and Non-Small-Cell Lung Can-
cer (NSCLC), which accounts for approximately the remaining 85% [3]. The latter is once 
again differentiated into three main subtypes: adenocarcinoma, Squamous Cell Carcinoma 
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AbstrAct
BACKGROUND: Unlike the tissue one, liquid biopsy is a less invasive diagnostic method for the assessment of possible 
mutations of the tumor, based on the analysis of circulating free DNA (cfDNA) present in the plasma component of the 
blood. Because blood samples are easily obtainable, plasma biopsy is a non-invasive method, supplementing the more 
traditional biopsy techniques.
AIM: A cost-consequence analysis was conducted to compare the adoption of three different diagnostic strategies in the 
first- and second-line treatment of locally advanced or metastatic NSCLC: i) tissue strategy (only tissue biopsy for first and 
second line), ii) combined strategy (first line: tissue biopsy. If unknown, liquid biopsy; second line: liquid biopsy. If nega-
tive, tissue biopsy) and iii) potential strategy (first line: tissue biopsy. If unknown or tissue ineligible, liquid biopsy; second 
line: liquid biopsy. If negative, tissue biopsy).
METHODS: A decision-analytic model was developed considering the Italian NHS’s perspective. We only evaluated di-
rect medical costs (tissue biopsy, management of complications associated with tissue and liquid biopsies) borne by the 
NHS. The CCA was conducted over a time horizon of 1 year, assuming that for each patient with mNSCLC the diagnostic 
pathway (first- and second-line treatment) ended within such period. Key variables were tested in the sensitivity analysis. 
RESULTS: Considering both the first and the second line of treatment, the potential strategy constitutes the cost-effective 
alternative, characterized by an average cost per correctly identified case (€ 685) lower than that estimated for the combined 
strategy (€ 732) or for the tissue strategy (€ 1,004). The potential strategy remains cost-effective, also considering the re-
sults referred to the first- or second-line treatment only.
CONCLUSION: The choice of a correct diagnostic strategy is crucial in order to optimize cancer therapies in the first- and 
second-line treatment of locally advanced or metastasized NSCLC. The addition to the diagnostic pathway of the liquid 
biopsy would correctly identify a greater number of cases, supporting the prescription of the best oncological therapy.
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(SCC), and Large Cell Carcinoma (LCC). NSCLC can, therefore, be considered as a hetero-
geneous set of tumors, with different histological and biomolecular characteristics [4].
In the era of personalized treatments (targeted therapies), histocitopathological diagnosis 
is a priority in the process of selection of the most appropriate cancer treatment [5]. Therefore, 
this selection increasingly more often should be based on the correspondence between the 
drug profile and the specific mutation of the primary tumor [6,7]. For example, tests for EGFR 
(Epidermal Growth Factor Receptor) and ALK (Anaplastic Lymphoma Kinase) mutations are 
recommended to support oncologists in the choice of the first- and second-line treatment in 
non-squamous cell carcinomas [7]. This trend is expanding the screening of other biomolecu-
lar alterations, including ROS1, BRAF and MET, among others.
In the majority of cases, the histocitopathological diagnosis is made by examining a lung 
tissue sample taken by tissue biopsy. By means of particular techniques of preparation and 
staining of the sample, the pathologist can then make a diagnosis and identify the type of 
cancer [8]. The pathologist can also perform the subsequent molecular analyses on the mate-
rial collected, in order to obtain more information about the prognosis and the predictability 
of effectiveness of a certain treatment. However, tissue biopsy poses several limitations, for 
example when it is not possible to acquire an adequate amount of tissue to conduct all the 
molecular analyses [9].
The targeted diagnostic/therapeutic approach to the tumor requires the integration of con-
ventional histopathological diagnostics with molecular characterization of the tumor. It means 
that, in order to implement an individualized cancer therapy, the identification of the molecu-
lar alterations characterizing the tumor is necessary, in addition to the organic and morpho-
logical classification.
In the absence of a molecular analysis, the choice of treatment will be directed towards 
chemotherapy in combination with cisplatin, thus precluding – in case of a patient with a 
specific mutation – the benefits resulting from the administration of a targeted therapy [5]. 
Generally, the disease progression requires a second line of treatment, which is indicated only 
for patients with an acceptable Performance Status (PS) [5]. In addition, in the metastatic 
stage, lung cancer often develops resistance to the first-line therapy. For example, in patients 
with sensitizing EGFR mutations (classically, exon 19 deletion; point mutation in exon 21), 
the resistance to EGFR tyrosine kinase inhibitors can be determined by the onset of the EGFR 
T790M mutation [10], or by mechanisms of the by-pass track type, like the presence of am-
plification of the MET gene, or by a change in the carcinoma histology [9]. Therefore, every 
time the cancer recurs or progresses, it would be appropriate to conduct additional molecular 
analyses, in order to identify the most appropriate cancer treatment.
In patients with progressing NSCLC, the repetition of the tissue biopsy may result in an 
increased risk of complications related with the diagnostic surgical procedures, or it could not 
even be feasible, due to the clinical conditions (PS) of the patient. In the latter case, in the 
presence of a mutation, the patient may be precluded from the benefits of a targeted therapy. 
Therefore, a clinical unmet need emerges and it requires an alternative procedure for the tis-
sue biopsy.
Unlike the tissue one, liquid biopsy is a less invasive diagnostic method for the assessment 
of possible mutations of the tumor, based on the analysis of circulating free DNA (cfDNA) 
present in the plasma component of the blood [11]. Because blood samples are easily obtain-
able, plasma biopsy is a non-invasive method, supplementing the more traditional biopsy 
techniques. Liquid biopsy, moreover, can trace the prevalent DNA-releasing tumor popula-
tion, considering the presence of numerous cell clones present in the primary tumor and in the 
metastatic sites. It is, therefore, a more “dynamic” method, which can trace the evolutionary 
process of a tumor exposed to the various selective pressures determined by the selected sys-
temic or local therapies. The COBAS® EGFR Mutation Test v2 (Roche Molecular Systems, 
Inc., henceforth COBAS® test) is an oncology test that can be performed on plasma samples 
(liquid biopsy), in addition to tissue ones, and which, if necessary, allows to avoid the risks 
related to tissue biopsy and to the poor availability of the sample, which are an obstacle to 
the adoption of the molecular test. The COBAS® test uses real-time PCR technology for the 
detection and identification of the mutations of the EGFR gene (identification of 42 mutations 
in exons 18, 19, 20 and 21) in the DNA derived from plasma or from tumor tissue in patients 
with NSCLC, and is designed as an aid in the selection of the patients suffering from this 
disease and eligible for the treatment with EGFR tyrosine kinase inhibitors.
When addressing the issue of sustainability and efficient allocation of health resources, se-
rious attention should be paid not only to the clinical aspects but also to the economic impact 
possibly deriving from a chosen diagnostic pathway.
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The aim of the present cost-consequence analysis (CCA) was to evaluate the economic 
impact generated by the adoption of three different diagnostic strategies in the first- and sec-
ond-line treatment of locally advanced or metastatic NSCLC (adenocarcinoma, squamous cell 
carcinoma and large cell carcinoma), henceforth mNSCLC: i) tissue strategy, ii) combined 
strategy and iii) potential strategy.
Methods
Analysis technique
With a view to overall sustainability, it is therefore important to optimize the diagnostic 
strategy of a mNSCLC patient, identifying the most convenient one in terms of both clinical 
benefit and costs. In line with this objective, a cost-consequence analysis (CCA) [12,13] was 
conducted. In a CCA the economic impact is estimated of costs and effects, regardless of a 
formal assessment of cost effectiveness. In other words, a CCA is substantially a list of the 
significant costs and consequences of an intervention
Study design
The CCA was conducted from the Italian National Health System (NHS) perspective. A 
decision-analytic model was developed to compare the three different diagnostic strategies in 
the first- and second-line treatment of mNSCLC. The tissue and combined strategies describe 
the clinical practice, while the potential strategy represents a hypothetical diagnostic pathway.
The tissue strategy (Figure 1A) provides for the execution of the tissue biopsy only for 
patients eligible to perform the tissue diagnostic investigation and to receive the first line of 
treatment; no additional diagnostic investigation is provided for the rest of patients who are 
eligible for treatment, but not for tissue biopsy. In the event of disease progression (second-
line treatment), the strategy provides for the execution of a second tissue biopsy for all pa-
tients eligible for the tissue re-biopsy and the second-line treatment [3]. For the other patients 
eligible for treatment, but not for the tissue re-biopsy, no diagnostic investigation is provided. 
The combined strategy (Figure 1B) provides for the execution of the tissue biopsy in all pa-
tients eligible for the diagnostic investigation and the first-line treatment; for all cases where 
it was not possible to determine the outcome from the first tissue biopsy, the liquid biopsy 
is also performed. For patients eligible for treatment, but not for a tissue biopsy, no further 
biopsy procedure is provided. Unlike the tissue strategy, in the event of disease progression 
(second-line treatment), the execution of the liquid biopsy in all patients eligible to receive the 
second-line treatment is provided. If the outcome of the liquid biopsy is negative, a successive 
tissue biopsy is performed on those patients eligible for tissue re-biopsy. The potential strat-
egy (Figure 1C) is entirely similar to the combined one, with the exception of what happens 
to patients eligible for the first line of treatment, but not eligible to the tissue biopsy; these 
patients are subjected to liquid biopsy.
Only tissue and liquid biopsies costs and the cost of complications associated with tis-
sue biopsy were considered. No cost of complications associated with liquid biopsy were 
assumed. Other direct medical costs (eg. cancer treatment) and indirect costs (eg. loss of 
productivity) were not evaluated. The CCA was conducted over a time horizon of 1 year, as-
Figure 1. Diagnostic strategies compared in the analysis
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suming that for each patient with mNSCLC 
the diagnostic pathway (first- and second-line 
treatment) ended within such period. This hy-
pothesis is certainly a limitation with respect 
to what happens in clinical practice – where 
patients with different prognoses are charac-
terized by different treatment durations – but 
it allows to estimate the potential financial 
impact of the three strategies against a spe-
cific time period, which is a crucial element in the decision-making processes.
input data of the model
Population
The estimated number of patients included in the CCA, reported in detail in Table I, was 
calculated starting from the number of new cases of lung cancer expected for 2017 in Italy 
(sample size) [1]. From these, the cases of NSCLC were first calculated [3], and then those 
with a diagnosis of adenocarcinoma, squamous cell carcinoma or large cell carcinoma were 
identified [14]. Then, only the cases relating to subjects with locally advanced or metastasized 
diagnosis [15] eligible for the first line of treatment [3] were considered. It is estimated that 
85% of these patients are eligible for the tissue biopsy [2], while the remaining 15% poten-
tially to the liquid biopsy only. Among the patients who perform the tissue biopsy, the out-
come may not be determinable in 30% of cases [16]. Finally, 40% of patients with a mNSCLC 
diagnosis are eligible to receive the second-line treatment [3]; of them, 82% are eligible for 
the tissue re-biopsy [5] and 100% for the liquid one.
Clinical data
Table II shows the percentages of sensitivity and specificity associated with the COBAS® 
test performed on tissue (tissue biopsy) or plasma (liquid biopsy) samples and considered here 
[17,18]. In addition to these data, in the model – based on what is indicated in the literature 
– in the presence of a tissue biopsy, a 14% probability that the diagnostic investigation could 
determine the onset of a post-procedure complication (eg. pneumothorax) was considered 
[19]. The likelihood of such occurrence was set equal to 0% in the presence of a liquid biopsy.
Biopsy cost and complications
Table III shows the costs associated with the implementation of the tissue or liquid biopsy. 
The tissue biopsy provides for the execution of the biopsy of the pleura or the bronchus and 
the subsequent procedures aimed at determining the presence of DNA mutations (DNA muta-
tion analysis, DNA digestion with restriction enzymes and extraction of DNA or RNA). In 
the case of the liquid biopsy, instead, in addition to the execution of the activities aimed at 
Parameters Population (n.) Source
New patients with lung cancer (year 2017) 41,800 [1]
Patients with NSCLC (83.0%) 34,694 [3]
Patients with adenocarcinoma, squamous cell carcinoma or large cell carcinoma (67.0%) 23,245 [14]
Patients with locally advanced or metastasized diagnosis (74.1%) 17,225 [15]
First-line treatment
Patients eligible for the first-line treatment (89.0%) 15,330 [3]
Patients eligible for the tissue biopsy (85.0%) 13,030 [2]
 • Determinable outcome (70.0%) 9,121 Calculated from [16]
 • Non-determinable outcome (30.0%) 3,909 [16]
Patients not eligible for tissue biopsy, but eligible for liquid biopsy (15.0%) 2,299 Calculated from [2]
Second-line treatment
Patients eligible for the second-line treatment (40.0%) 6,890 [3]
Patients eligible for the tissue re-biopsy (82.0%) 5,650 [5]
Patients eligible for the liquid biopsy (100.0%) 6,890 Assumption
Table i. Estimated number of patients included in the CCA
egFr 
mutations
Liquid biopsy Tissue biopsy
Sensitivity 
(%)
Specificity 
(%)
Sensitivity 
(%)
Specificity 
(%)
Exons 19, 21 95.0 91.0 98.1 99.3 
T790M 93.0 92.0 90.0 98.0
Table ii. Percentages sensitivity and specificity associated with the COBAS® 
EGFR Mutation Test [17,18]
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determining the presence of DNA mutations, 
only the sampling of venous blood is pro-
vided for. Every single specialist outpatient 
service was then attributed a value, consider-
ing the respective fee refunded by the NHS 
[20]. Thus, it was then estimated an average 
cost of € 412.02 for the tissue biopsy and of 
€ 233.86 for the liquid one.
The onset of a post-tissue biopsy com-
plication was instead esteemed considering 
a value of € 2,541.50, obtained as a simple 
average between the amounts reimbursed 
for DRG 094 (pneumothorax with complica-
tions: € 3,265) and DRG 095 (pneumothorax 
without complications: € 1,818) [21].
Output data of the model
Cost-effectiveness ratio (CER)
On the basis of the eligible population and the estimated average cost for the (tissue and/
or liquid) biopsy and for the complications, the CCA provides – for the three diagnostic strate-
gies, over a time horizon of one year – the number of eligible patients, the number of correctly 
identified cases and the total cost of the strategies. The difference in the spending borne by 
the NHS generated by the three different diagnostic strategies is presented in terms of average 
cost per correctly identified case (CER).
Sensitivity analysis
The sensitivity analysis was conducted with the aim of evaluating the degree of uncer-
tainty of the base case results [22]. A first part of the sensitivity analysis was carried out by 
varying some epidemiological data used – in the base case – to estimate the number of the 
cases eligible for the three different diagnostic strategies. Specifically, with reference to the 
first line of treatment, and differently from what was done in the base case it has been hypoth-
esized that all patients are eligible for the tissue biopsy (from 85% of the base case to 100%). 
It was also verified the impact associated with the reduction in the percentage of cases where 
the outcome cannot be determined after the first tissue biopsy, actually halving the probability 
adopted in the base case (from 30% to 15%). With reference to the second-line treatment, it 
was finally assumed a scenario in which the percentage of the cases eligible for the liquid 
biopsy was reduced, and set equal to that used for the tissue re-biopsy (82%).
The second part of the sensitivity analysis was focused on the clinical data. In particular, 
compared to the base case, the sensitivity and specificity of the liquid biopsy in determining 
EGFR mutations (T790M and exons 19 and 21) was varied, by simultaneously considering 
(multivariate analysis) the respective lower limits of the confidence interval [17], while leav-
ing unchanged the values of sensitivity and specificity associated with the tissue biopsy. With 
regard to the presence of the post-tissue biopsy complications, conservatively with respect to 
the base case, a 50% reduction in complications (from 14% to 7%) was assumed.
The third and final part of the sensitivity analysis was conducted on the cost used to assign 
a value to the management of post-tissue biopsy complications. Conservatively, the lowest 
value (€ 1,818) associated with the DRG 095 expected in case of pneumothorax without com-
plications was considered.
results
economic impact
Considering both the first and the second line of treatment, the potential strategy consti-
tutes the cost-effective alternative, characterized by an average cost per correctly identified 
case (€ 685) lower than that estimated for the combined strategy (€ 732) or for the tissue strat-
egy (€ 1,004) (Table IV). This is due to the greater use of the liquid biopsy, which allows the 
potential strategy to significantly increase the number of correctly identified cases (+10.9% vs 
combined strategy; +50.5% vs. tissue strategy), against a slight increase in the spending borne 
by the NHS (+3.8% vs combined strategy; +2.7% vs tissue strategy) (Table IV and Figure 2). 
The potential strategy remains cost-effective, also considering the results referred to the first- 
or second-line treatment only.
Procedures
Unit cost (€)
Tissue 
biopsy
Liquid 
biopsy
34.24 Pleural or 33.24 bronchial biopsy 180.74 0.00
91.49.2 Venous blood sampling 0.00 2.58
DNA mutations 231.28 231.28
 • 91.29.4 DNA mutation analysis 120.80 120.80
 • 91.36.4 DNA digestion with restriction enzyme 51.43 51.43
 • 91.36.5 Extraction of DNA or RNA 59.05 59.05
Total 412.02 233.86
Table iii. Costs associated with the tissue and liquid biopsy
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With regard to the first line of treatment 
(Table IV), the patients eligible for the po-
tential strategy are 15,330, while 13,030 
are those eligible for the tissue or combined 
strategy. The difference of 2,299 patients 
(17.6%) is due to the extension of use of the 
liquid biopsy for the subjects eligible for the 
cancer therapy, but not eligible for the tissue 
biopsy. By virtue of this, the number of cor-
rectly identified cases – with respect both to 
the combined strategy (14,733 vs. 12,624) 
and the tissue strategy (14,733 vs. 9,037) – 
increases. Given this greater effectiveness, 
despite an increase in costs (+4.9% vs com-
bined strategy; 14.5% vs tissue strategy), 
the potential strategy – with an average cost 
per correctly identified case of € 778 – de-
termines the most efficient allocation for the 
NHS.
Even considering the second-line treat-
ment only (Table IV), the number of eligible 
patients differs between the three diagnostic 
strategies: 5,650 for the tissue strategy and 
6,890 for the combined or potential ones. 
The difference (1,240 patients) is due to the 
different approach adopted by the strategies: 
in the tissue strategy, only the use of the tis-
sue biopsy is provided for, while in the other 
two strategies the use of the liquid biopsy is 
called for, followed – if unsuccessful – by the 
execution of a subsequent tissue biopsy. The 
approach followed by the combined or po-
tential strategy allows determining a greater 
number of correctly identified cases, com-
pared to the tissue strategy (6,770 vs 5,251; +28.9%). Unlike the estimates for the first line of 
treatment, the tissue strategy determines the higher costs borne by the NHS (€ 4,337,973 vs € 
3,270,878; +32.6%). Therefore, against a greater effectiveness and lower costs, in the second 
line of treatment, the combined and potential strategies are dominant compared to the tissue 
one (Table IV).
 
Tissue 
strategy
Combined 
strategy
Potential 
strategy
First- and second-line treatment
Eligible patients (n.) 18,680 19,920 22,220
Correctly identified cases (n.) 14,288 19,394 21,504
Total cost (€) 14,343,085 14,190,174 14,727,930
Average cost per correctly 
identified case (€)
1,004 732 685
First-line treatment
Eligible patients (n.) 13,030 13,030 15,330
Correctly identified cases (n.) 9,037 12,624 14,733
Total cost (€) 10,005,112 10,919,297 11,457,052
 • Tissue biopsy cost (€) 5,368,774 5,368,774 5,368,774
 • Liquid biopsy cost (€) 0 914,185 1,451,941
 • Post-tissue biopsy 
complications cost (€)
4,636,337 4,636,337 4,636,337
Average cost per correctly 
identified case (€)
1,107 865 778
Second-line treatment
Eligible patients (n.) 5,650 6,890 6,890
Correctly identified cases (n.) 5,251 6,770 6,770
Total cost (€) 4,337,973 3,270,878 3,270,878
Tissue biopsy cost (€) 2,327,770 890,560 890,560
 • Liquid biopsy cost (€) 0 1,611,253 1,611,253
 • Post-tissue biopsy 
complications cost (€)
2,010,203 769,065 769,065
 • Average cost per correctly 
identified case (€)
826 483 483
Table iV. Results
Figure 2. Results for first- and second-line treatment
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Sensitivity analysis
Table V shows the results of the sensitiv-
ity analysis, expressed in terms of average to-
tal cost (first and second line of treatment) per 
correctly identified case. In all comparisons, 
the potential strategy remains cost-effective.
Some results produced by the sensitiv-
ity analysis, however, deserve some thought. 
Both the reduction in the percentage of pa-
tients with post-tissue biopsy complications 
and the decrease in the average cost con-
sidered to assign a value to such eventual-
ity affect significantly the base case results, 
reducing both the average cost per correctly 
identified case and the relative differences 
(Table V). The reduction of the probability 
that a patient in the first line can have a tissue 
biopsy with undetermined outcome affects 
predominantly the results of the comparison 
between tissue and combined strategy, reduc-
ing by more than 30% the difference between 
the two average costs compared to the base case (Table V). Finally, the adoption of the hy-
pothesis that in the first line of treatment all patients are eligible for the tissue biopsy affects 
mainly the potential strategy, making it – in actual fact – equivalent to the combined one (the 
subjects undergoing the liquid biopsy following an undetermined outcome of the previous 
tissue biopsy would in fact be excluded).
dIscussIon
A CCA was conducted, in order to assess the financial impact on the Italian NHS resulting 
from the adoption of three different diagnostic strategies in the first- and second-line treatment 
of mNSCLC. The decision-analytic model allowed to estimate, for each of the three alterna-
tive strategies, the clinical and economic consequences in terms of average cost per correctly 
identified case.
The potential strategy reported a lowest average cost per correctly identified case (€ 685) 
compared to the combined or tissue strategies (€ 732 and € 1,004, respectively). This result 
is due to the greater number of patients that the potential strategy allows to correctly identify 
compared to the two alternatives (+10.9% vs combined strategy; +50.5% vs. tissue strategy), 
against a slight increase in expenditure (+3.8% vs combined strategy; +2.7% vs tissue strat-
egy). By limiting the observation to the comparison between the tissue and the combined 
strategy, it is evident that the latter is dominant, with a larger number of correctly diagnosed 
cases (5,106) and a lower spending (-152,910 €).
As it happens whenever the use of a simulation model is necessary, it is appropriate to in-
terpret the results in light of a few considerations. The epidemiological analysis, on which this 
CCA is based, was conducted with the objective of defining, from a common sampling frame 
(number of new cases of lung cancer), the number of patients eligible for the three diagnostic 
strategies investigated. This process was conducted using data from different bibliographic 
sources and, in the absence of them, making some assumptions. To limit the uncertainty as-
sociated with this process, a wide sensitivity analysis was conducted on the major epidemio-
logical variables that can affect the outcome of the base case. If in the first-line treatment the 
percentage of patients eligible for tissue biopsy switched from 85% (base case) to 100%, the 
combined and potential strategies would lead to the same average cost per correctly identified 
case, while remaining both cost-effective compared to the tissue strategy. While it would not 
change the results of the base case, the reduction (from 30% to 15%), in the first-line treat-
ment, of the probability that a patient may have a tissue biopsy with an undetermined outcome 
would result in a significant decrease in the average cost per correctly identified case associ-
ated with each of the three strategies. Whereas the reduction in the second-line treatment of 
the percentage of patients eligible for the liquid biopsy (from 100% to 82%) would not alter 
at all the results of the base case.
The sensitivity analysis – conducted on the sensitivity and specificity of the COBAS® test 
and on the probability that a complication related to the tissue biopsy could occur – confirmed 
Average total cost per correctly 
identified case (€)
Tissue 
strategy
Combined 
strategy
Potential 
strategy
Base case 1,004 732 685
Patients eligible for the tissue biopsy 
– first-line treatment = 100%
1,014 745 745
Patients with outcome not 
determined after the first tissue 
biopsy – first-line treatment = 15%
884 703 659
Patient eligible for the liquid biopsy – 
second-line treatment = 82%
1,004 748 697
Lower ends of the CI of the value of 
sensitivity and specificity associated 
with the tissue biopsy
1,004 742 697
Post-tissue biopsy complications = 7% 771 592 559
Management of post-tissue biopsy 
complication = DRG 095
871 652 613
Table V. Sensitivity analysis
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in the first case the results of the base case, while in the second case it showed a significant 
reduction in the three average costs of per correctly identified case, confirming, however, the 
cost-effectiveness of the potential strategy.
The adoption of a more conservative criterion to assign a value to the management of the 
post-tissue biopsy complication (DRG 095 pneumothorax without complications: € 1,818) 
would confirm, for the potential strategy, the lower average cost per correctly identified case.
Finally, it is to be emphasized that this analysis assessed only the consequences arising 
from the choice of one of the three different diagnostic strategies, measured in terms of costs 
per biopsy/complication and per correctly identified case, net of the consequences that this 
choice could have on the cost of the cancer treatment or on survival (overall or progres-
sion-free) of the patient. The possibility of carrying out a molecular analysis each time it is 
necessary, regardless of the patient’s Performance Status, would allow to identify the most 
appropriate cancer treatment, thus consenting to maximize the effectiveness of the treatment 
pathway and minimize the waste of healthcare resources.
conclusIons
The results found here show how the choice of a correct diagnostic strategy is crucial in 
order to optimize cancer therapies in the first- and second-line treatment of locally advanced 
or metastasized NSCLC. The mere use of the tissue biopsy proved not to be cost-effective, 
while the addition to the diagnostic pathway of the liquid biopsy would instead make it pos-
sible to correctly identify a greater number of cases, supporting the prescription of the best 
oncological therapy.
It is therefore believed that this analysis, despite its limitations, managed to present a con-
vincing scenario deriving from the adoption of three different diagnostic strategies aimed at 
making the mNSCLC patient’s therapeutic pathway more efficient. It would be desirable, in 
the future, to be able to compare such result with what will be evidenced by clinical practice.
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